Introduction

Datamonitor estimates 2009 allergic rhinitis sales of $5 billion in the seven major markets, and forecasts a decline to $4 billion by 2019. The greatest threat to the market is generics, with drug classes having differing vulnerability to generic erosion. While the symptomatic treatment sales will decrease, immunotherapy sales are on the rise, with changing regulations dictating development.

Reasons to Purchase

*Understand allergic rhinitis market trends, including life cycle management, current sales, and a 10 year sales forecast of symptomatic treatments

*Gain insight into the immunotherapy market and access patient based forecasts of three key immunotherapy products, with interactive assumptions

*Assess analysis of key companies in the market and see how allergic rhinitis contributes to total brand sales

[Studien Infos ausblenden]

#NV
[Inhaltsverzeichnis ausblenden]